A Pivotal Year for PHC. Inc

Hoffman, Tony
September 2004
Equities;Fall/Winter2004, Vol. 52 Issue 2, p19
The article presents information on the financial performance of the Pioneer Behavioral Health Inc. (PHC). In May, 2004 PHC acquired Phoenix-based Pivotal Research Centers LLC, in a deal for $1.5 million and $500,000 in PHC stock, as well as performance-based incentives. Pivotal is a pharmaceutical research and clinical trials company, between 75% and 80% of its work is in central nervous system research. It has a 10-year reputation and counts nearly all the large pharmaceutical companies as its clients.


Related Articles

  • The Rise and Fall of NMDA Antagonists for Ischemic Stroke. Hoyte, L.; Barber, P.A.; Buchan, A.M.; Hill, M.D. // Current Molecular Medicine;Mar2004, Vol. 4 Issue 2, p131 

    It has long been accepted that high concentrations of glutamate can destroy neurons, and this is the basis of the theory of excitotoxicity during brain injury such as stroke. Glutamate N-methyl- D-aspartate (NMDA) receptor antagonists such as Selfotel, Aptiganel, Gavestinel and others failed to...

  • Other CNS News Headlines August 15, 2003 - September 14, 2003.  // PharmaWatch: CNS;October 2003, Vol. 2 Issue 10, p19 

    Presents new headlines regarding clinical trials for the treatment of central nervous system diseases as of August 15, 2003. Approval received by GlaxoSmithKline and Bayer for viagra rival; Clinical trial for MaroChem erectile dysfunction drug; Requests by Food and Drug Administration to submit...

  • COMPANY SPOTLIGHT-- Eli Lilly and Company.  // PharmaWatch: CNS;August 2004, Vol. 3 Issue 8, p19 

    The article presents information on Eli Lilly and Company's plans to disclose the results of all clinical trials for which it is a sponsor. The Indianapolis-based group will place all the data on a publicly available registry. The registry will include results of all phase I through phase IV...

  • Prevention of heterotopic ossification after spinal cord injury with COX-2 selective inhibitor (rofecoxib). Banovac, K.; Williams, J. M.; Patrick, L. D.; Levi, A. // Spinal Cord;Dec2004, Vol. 42 Issue 12, p707 

    STUDY DESIGN::A randomized, prospective, double-blind, placebo-controlled clinical trial. OBJECTIVES::To determine the effect of COX-2-selective inhibitor on the prevention of heterotopic ossification (HO) after spinal cord injury (SCI). SETTING::County and University Teaching Hospital, Miami,...

  • Analgesics okay in children with abdominal pain.  // Journal of Family Practice;Feb2006, Vol. 55 Issue 2, p105 

    The article cites a randomized controlled trial regarding the safety and efficacy of analgesic for treatment of children with acute abdominal pain requiring surgical consultation. The study enrolled 108 children presenting to the emergency department of a tertiary care hospital. These patients...

  • Interferone und Natalizumab in der Behandlung der multiplen Sklerose (MS). Clar, Christine; Garrido, Marcial Velasco; Gericke, Christian; Busse, Reinhard // GMS Health Technology Assessment;2009, Vol. 5, p1 

    Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system which is accompanied by considerable disability and high costs. This report summarises the evidence on effectiveness and costs of beta-interferons and natalizumab in the treatment of multiple sclerosis. The...

  • Immunotherapy plus high-dose chemotherapy effective in primary CNS lymphoma. Rubenstein, James L. // Hem/Onc Today;5/25/2013, Vol. 14 Issue 10, p36 

    The article discusses the findings of the Cancer and Leukemia Group B Alliance 50202 clinical trial which demonstrated the feasibility of high-dose chemotherapy consolidation in a multicenter setting in patients with newly diagnosed primary central nervous system lymphoma.

  • Treatment of partial seizures in childhood : an overview. Coppola, Giangennaro // CNS Drugs;2004, Vol. 18 Issue 3, p133 

    The treatment of partial seizures in children is based on the use of first generation and recently introduced antiepileptic drugs as well as nonpharmacological treatments such as the ketogenic diet, vagus nerve stimulation and surgical therapy. The present review discusses the efficacy and...

  • The Big Picture.  // PRWeek (London);10/1/2013, p7 

    The article reports on the greater emphasis of corporations in 2013 to take good care of their reputation, which comes after it was found that it significantly influences their financial performance.


Read the Article

Other Topics